Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Extensive-stage Small-cell Lung Cancer|Locally Advanced Breast Cancer|Metastatic Breast Cancer|Platinum-sensitive Ovarian Cancer|Platinum-Sensitive Fallopian Tube Carcinoma|Platinum-Sensitive Peritoneal Cancer
Interventions: DRUG: RP12146
Sponsor: Rhizen Pharmaceuticals SA